Bycus Therapeutics Private Limited, a active private limited company, was established on 23 April 2020 in Gachibowli, Telangana, India. Engaging in biotechnology within the professional, scientific and technical sector, it holds CIN: U73200TG2020PTC140175. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹4.00 M and a paid-up capital of ₹2.33 M.
It upholds a compliant status. Employing 46 professional, Its leadership includes Lavanya Sunkara (Director), Nageswara Rao Pulipati (Director), Nishanth Pasaru (Director). Past directors included Nishanth Pasaru. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Suite No.13, Ouh Bio-Nest School Of Lifesciences, C/O University Of Hyderabad, Gachibowli, Telangana, 500046.
U73200TG2020PTC140175
140175
23 April 2020
₹4.00 M
₹2.33 M
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Bycus Therapeutics Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Lavanya Sunkara | Director | 23 Apr 2020 | Current |
| Nageswara Rao Pulipati | Director | 23 Apr 2020 | Current |
| Nishanth Pasaru | Director | 23 Apr 2020 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Managing Director | 12 Mar 2022 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Bycus Therapeutics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 71.66% decrease. The company also saw a substantial fall in profitability, with a 127.36% decrease in profit. The company's net worth Soared by an impressive increase of 245.63%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Bycus Therapeutics had a public holding of 14.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Bycus Therapeutics has a workforce of 46 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Bycus Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bycus Therapeutics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Bycus Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Progress on Bycus Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was documented.
Lavanya Sunkara was appointed as a Director was appointed as a Director on 23 Apr 2020 & has been associated with this company since 5 years 7 months . was recorded as a recent event.
The activity Nageswara Rao Pulipati was appointed as a Director was appointed as a Director on 23 Apr 2020 & has been associated with this company since 5 years 7 months . was completed.
Nishanth Pasaru was appointed as a Director was appointed as a Director on 23 Apr 2020 & has been associated with this company since 5 years 7 months . was recorded as a recent event.
The activity Bycus Therapeutics Private Limited was registered on 23 Apr 2020 with Roc Hyderabad & aged 5 years 7 months as per MCA records. was completed.
The CIN of Bycus Therapeutics Private Limited is U73200TG2020PTC140175.
Bycus Therapeutics Private Limited is headquartered at Suite No.13, Ouh Bio-Nest School Of Lifesciences, C/O University Of Hyderabad, Gachibowli, Telangana, 500046.
Bycus Therapeutics Private Limited was incorporated on 23 April 2020.
The current directors of Bycus Therapeutics Private Limited are
The primary industry of Bycus Therapeutics Private Limited is Professional, Scientific And Technical.
Bycus Therapeutics Private Limited is unlisted.
The authorized capital of Bycus Therapeutics Private Limited is ₹4.00 M, and the paid-up capital is ₹2.33 M.
The compliance status of Bycus Therapeutics Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX